Install
Clinical Trials (Phases I–IV)
Design, endpoints, enrollment, interim reads, and post‑market surveillance.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Clinical Trials (Phases I–IV)
H. Lundbeck A/S (OMXCOP:HLUN_A) Completes Randomization in Phase III Dravet Trial
4+ hour, 22+ min ago (128+ words) TradingView H. Lundbeck A/S (OMXCOP:HLUN_A) Completes Randomization in Phase III Dravet Trial H. Lundbeck A/S said the last patient has been randomized in DEEp SEA, a global Phase III trial of bexicaserin for seizures in Dravet syndrome; over 100 participants enrolled,…...
A Single Dose of Pharmaceutical LSD Cut Anxiety Scores Five Points Below Placebo in Phase 3 Trial
12+ hour, 53+ min ago (773+ words) A single dose of a pharmaceutical formulation of LSD cut anxiety scores by about 5 points more than placebo over 12 weeks, according to topline results from the Panorama study released Monday by Definium Therapeutics. Panorama enrolled 245 adults with generalized anxiety disorder…...
Definium’s DT120 ODT Meets Primary Endpoint in Phase 3 GAD Study
5+ hour, 15+ min ago (321+ words) clinicaltrialvanguard.com Definium’s DT120 ODT Meets Primary Endpoint in Phase 3 GAD Study Definium Therapeutics reported positive topline data from its Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder on September 14, 2026, a result that matters because GAD pharmacotherapy has run on…...
VSTM: Advancing RAS/MAPK therapies with pivotal trials and new data to expand cancer treatment options
16+ hour, 25+ min ago (81+ words) TradingView VSTM: Advancing RAS/MAPK therapies with pivotal trials and new data to expand cancer treatment options The session highlighted progress in commercial and clinical programs for RAS/MAPK-driven therapies, including a strong launch for the CO-PACK in ovarian cancer…...
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
1+ day, 8+ hour ago (484+ words) Definium Therapeutics to Discuss Topline Results from Phase 3 Pan The National Law Review Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 Company to host webcast tomorrow at 8:00 a.m. EDT NEW YORK--(BUSINESS WIRE)…...
Can Acetylcholine Receptor Antibody Profiling Predict FcRn Therapy Outcomes in MG?
4+ day, 10+ hour ago (296+ words) Dr. Iorio: My name is Raffaele Iorio. I’m an associate professor of neurology at the Universita Cattolica del Sacro Cuore in Rome, Italy. I am also a staff neurologist at the Fondazione Policlinico Gemelli in Rome, Italy. Rare Diseases Today:…...
ARWR: Strong efficacy, safety, and launch readiness position plozasiran for high-impact SHTG entry
4+ day, 19+ hour ago (83+ words) tradingview.com Recent clinical data for plozasiran in SHTG show strong efficacy and a differentiated safety profile, with positive physician feedback and a focus on high-risk patient segments. Launch preparations are advanced, pricing has been well received by payers, and…...
Biovie seeks FDA meeting to plan Phase 3 trial for Parkinson's drug
4+ day, 22+ hour ago (532+ words) Planned study of bezisterim would enroll 175 adults with early-stage disease Written by Andrea Lobo | Sept. 10, 2026 Bezisterim, an experimental oral small molecule that Biovie is developing for people with early-stage Parkinson’s disease, is moving toward Phase 3 clinical testing, with the company…...
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
4+ day, 23+ hour ago (205+ words) Emerge Phase 3 study podium poster to be featured in “Latest Discoveries & Emerging Trends in MDD” session New epidemiological research on risks associated with anxiety and depression plus five posters across clinical program NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium…...
IFRX: INF904 advances in ANCA vasculitis with phase II trials planned and strong regulatory engagement
5+ day, 14+ hour ago (78+ words) TradingView IFRX: INF904 advances in ANCA vasculitis with phase II trials planned and strong regulatory engagement A strategic pivot prioritizes ANCA vasculitis with INF904, designed for better safety and efficacy, and vilobelimab as a bridging option amid competitor withdrawals. Regulatory engagement is…...